CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burgering, B. M.
Right arrow Articles by Bos, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burgering, B. M.
Right arrow Articles by Bos, J. L.

Cell Growth & Differentiation, Vol 5, Issue 3 341-347, Copyright © 1994 by American Association of Cancer Research


ARTICLES

Platelet-derived growth factor-induced p21ras-mediated signaling is independent of platelet-derived growth factor receptor interaction with GTPase-activating protein or phosphatidylinositol-3-kinase

BM Burgering, E Freed, L van der Voorn, F McCormick and JL Bos
Laboratory for Physiological Chemistry, Utrecht, The Netherlands.

Stimulation with platelet-derived growth factor (PDGF) results in the association of several SH2 domain-containing proteins with the activated PDGF receptor, including GAP, a GTPase-activating protein of p21ras, and phosphatidylinositol-3-kinase (PI-3K). To investigate the role of GAP-PI-3K receptor interaction in p21ras signaling, we have used cell lines expressing mutant PDGF receptors that either are impaired in GAP binding or fail to bind both GAP and PI-3K. In these cell lines, PDGF treatment resulted in activation of extracellular signal-regulated kinase 2 (ERK2), which could be blocked by the expression of a dominant-negative mutant of p21ras (p21ras(asn17)), indicating that these mutations in the PDGF receptor do not abolish p21ras-mediated activation of ERK2. In addition, the PDGF-induced increase in levels of p21rasGTP, as measured either in intact cells or in permeabilized cells, appears to be normal in the cell lines expressing the mutant PDGF receptors. These results indicate that binding of GAP and/or PI-3K to the PDGF receptor is not necessary for PDGF-induced p21ras activation and p21ras-mediated signaling to ERK2. We also show that, in contrast to the activation of ERK2, PDGF-induced GAP and PI-3K interaction with the PDGF receptor are not inhibited by p21ras(asn17) expression, indicating that these interactions do not require p21ras activation.


This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Auge, V. Garcia, F. Maupas-Schwalm, T. Levade, R. Salvayre, and A. Negre-Salvayre
Oxidized LDL-Induced Smooth Muscle Cell Proliferation Involves the EGF Receptor/PI-3 Kinase/Akt and the Sphingolipid Signaling Pathways
Arterioscler Thromb Vasc Biol, December 1, 2002; 22(12): 1990 - 1995.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
T. Suzuki, J. K-Tsuzuku, R. Ajima, T. Nakamura, Y. Yoshida, and T. Yamamoto
Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation
Genes & Dev., June 1, 2002; 16(11): 1356 - 1370.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. Z. Hossain, A. B. Jagdale, P. Ao, A. Kazlauskas, and A. L. Boynton
Disruption of Gap Junctional Communication by the Platelet-derived Growth Factor Is Mediated via Multiple Signaling Pathways
J. Biol. Chem., April 9, 1999; 274(15): 10489 - 10496.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1994 by the American Association of Cancer Research.